New $6.4M grant to test a preventive cancer vaccine in a dog clinical trial

Biodesign Institute's picture
Printer-friendly versionPrinter-friendly version

January 3, 2018

  • The Open Philanthropy Project awarded a multi-year grant of $6,421,402 to Stephen Albert Johnston and his team at Arizona State University to support the largest interventional canine clinical trial ever conducted.


    Download Photo

January 3, 2018

The Open Philanthropy Project awarded a multi-year grant of $6,421,402 to Stephen Albert Johnston at Arizona State University to support the largest interventional canine clinical trial ever conducted. The trial will assess the effectiveness of a unique vaccine in preventing any type of cancer in dogs. 

The trial will enroll at least 800 owners’ pets to test the efficacy of a novel vaccine to prevent cancer.

“Our goal has always been, that if this is possible, we should at least try it,” said Johnston, who directs the Biodesign Center for Innovations in Medicine. “Open Philanthropy was the only organization that responded to support our high-risk project, the biggest cancer intervention trial in dogs ever. I really admire them for that.

It is widely thought that all cancers are unique and therefore a general, preventative vaccine would not be possible.  However, Johnston’s team has discovered a potentially high-impact way of identifying tumor antigens that are common among cancers; these make up the key components of their vaccine.

The new vaccine, called a multi-valent frameshift peptide (FSP) vaccine, was developed by Johnston and his team over the last ten years.  The vaccine has been already tested for efficacy in mice and shown to be safe in dogs.

 

 Johnston and his team want to take the next leap and test the vaccine in humans. However, they feel that first testing the vaccine in dogs has many advantages. 

 

Cancer is the leading cause of death in pet dogs and their cancers are very similar to their human counterparts. Some breeds have a very high cancer rate, as much as 40 percent. The dog immune system responds to tumors and vaccines very similarly to humans.  But dog years and the course of tumor development are much shorter compared to the average human life span. Johnston thinks they can evaluate the effectiveness of the vaccine in five years or less, versus the 15 to 20 years it would take in a human trial. The vaccine they are testing in dogs will have a composition very similar to the one they would test in people.

 

“We have been working over 10 years to develop a vaccine that could potentially prevent any cancer,” said Luhui Shen, Ph.D., senior science director of the vaccine project.  “Our next goal is to test the vaccine in owner-enrolled, healthy dogs.  We are fairly confident that if the vaccine works in dogs, it could work in people.”

The trial will be conducted under the direction of Dr. Douglas Thamm, director of clinical research at the Flint Animal Cancer Center at Colorado State University. Healthy, middle-aged pet dogs will be enrolled, continuing to live their normal lives at home and receiving biannual exams with a complete clinical pathology workup. 

Dogs will be randomly chosen to receive either the vaccine or a mock version. Dogs receiving the mock vaccine are expected to develop cancer at normal rates. The experiment will determine whether the test vaccine can prevent cancers. Any owner whose dog develops cancer during the trial, on either the test or control arm, will be given a credit toward medical expenses. If successful, this trial would provide strong support for the concept of employing FSP vaccines to prevent cancer in its earliest stages, possibly leading to a canine cancer vaccine, and could eventually justify human clinical trials for both treatment and prevention.

 

“We consider this a high-risk project with an unusual opportunity for high impact as it could possibly reduce the incidence of cancer and cancer metastasis,” said an Open Philanthropy Project spokesperson. “We believe cancer preventative vaccines have a higher expected value than curative cancer therapies, since an effective vaccine would likely be a less expensive way to provide decades of healthy life compared to current cancer therapies, which often only extend life for a few months or years. We also believe cancer vaccines would be tractable in developing countries, which have a high cancer burden. FSP vaccines are particularly attractive compared to other proposed cancer vaccines because they may work against many cancer cell types.”

Cancer is increasingly placing a toll on developing countries, according to a World Health Organization report published in 2010. The latest WHO statistics cite that cancer causes around 7.9 million deaths worldwide each year. Of these deaths, around 70 percent, or 5.5 million deaths, are now occurring in the developing world. A disease once associated with affluence now places its heaviest burden on the poor and disadvantaged who could not afford the advanced treatments available in developed countries, some of which cost $200,000 or more. 

“If the vaccine works it should be inexpensive enough that everyone in the world could get it” according to Johnston.

Johnston foresees this commitment on the Open Philanthropy Project’s part to be an inspiration to other philanthropic efforts to be more daring and risk-taking.

“It wasn’t easy to identify an organization interested in funding such a trial,” said Johnston. “Open Philanthropy came to us, rigorously reviewed our proposal and offered to fund the trial.  We are extremely grateful that they would support this high-risk effort.  This vaccine may not work, but if it does it will be thanks to the commitment of Open Philanthropy to funding potentially transformative efforts.” Johnston is the director of the Biodesign Center for Innovations in Medicine and CEO of Calviri, Inc, a cancer vaccine company. He is known for his success as an innovator, inventor and disruptor of conventional science. Johnston and his interdisciplinary team have developed a system for continuous, comprehensive, inexpensive health monitoring known as immunosignature diagnostics. More recently, his team successfully answered a call from U.S. Department of Defense, the Defense Advanced Research Program Agency, or DARPA, to develop a technique for producing 1,000 doses of an antimicrobial in a week – a discovery that will potentially safeguard populations that are threatened by infections and outbreaks of Ebola and Zika. 

Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

6 + 2 =

To prevent automated spam submissions leave this field empty.